{
  "meta": {
    "id": "test10",
    "title": "Retina",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which drug causes the given presentation?",
      "options": [
        {
          "label": "A",
          "text": "Topical Steroids",
          "correct": false
        },
        {
          "label": "B",
          "text": "Topical Beta Blockers",
          "correct": false
        },
        {
          "label": "C",
          "text": "Topical PG Analogues",
          "correct": true
        },
        {
          "label": "D",
          "text": "Topical Cycloplegics",
          "correct": false
        }
      ],
      "correct_answer": "C. Topical PG Analogues",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture2_hPKDWFh.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Topical PG Analogues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Topical Steroids are used in the treatment of Cystoid Macular Edema .</li><li>\u2022 Option A</li><li>\u2022 Topical Steroids</li><li>\u2022 Cystoid Macular Edema</li><li>\u2022 Option B . Topical Beta Blockers are commonly used for glaucoma treatment and do not typically cause Cystoid Macular Edema. Their primary mechanism of action is reducing aqueous humor production in the eye .</li><li>\u2022 Option B</li><li>\u2022 Topical Beta Blockers</li><li>\u2022 glaucoma treatment</li><li>\u2022 primary mechanism</li><li>\u2022 action</li><li>\u2022 reducing aqueous humor production</li><li>\u2022 eye</li><li>\u2022 Option D . Topical Cycloplegics are used to paralyze the ciliary muscle and dilate the pupil . While they have various effects on the eye , they are not typically associated with causing Cystoid Macular Edema .</li><li>\u2022 Option D</li><li>\u2022 Topical Cycloplegics</li><li>\u2022 paralyze</li><li>\u2022 ciliary muscle</li><li>\u2022 dilate</li><li>\u2022 pupil</li><li>\u2022 eye</li><li>\u2022 causing Cystoid Macular Edema</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Topical Prostaglandin Analogues can cause Cystoid Macular Edema .</li><li>\u27a4 Topical Prostaglandin Analogues</li><li>\u27a4 Cystoid Macular Edema</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 602</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 602</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "39a29851",
      "audio": ""
    },
    {
      "text": "The Amount of the Drug in this implant is:",
      "options": [
        {
          "label": "A",
          "text": "500 \u00b5g",
          "correct": false
        },
        {
          "label": "B",
          "text": "700 \u00b5g",
          "correct": true
        },
        {
          "label": "C",
          "text": "52 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "36 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. 700 \u00b5g",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture1_48C9Wuq.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 700 \u00b5g</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The above picture shows a Intravitreal Dexamethasone Implant . It is a sustainable release biodegradable implant used in treatment of Cytoid Macular Edema S econdary to Retinal Vein Occlusion , Diabetic Maculopathy and other causes. 0.7mg of Dexamethasone is incorporated into this Implant .</li><li>\u2022 The above picture shows a Intravitreal Dexamethasone Implant .</li><li>\u2022 Intravitreal Dexamethasone Implant</li><li>\u2022 It is a sustainable release biodegradable implant used in treatment of Cytoid Macular Edema S econdary to Retinal Vein Occlusion , Diabetic Maculopathy and other causes.</li><li>\u2022 sustainable release biodegradable implant</li><li>\u2022 Cytoid Macular Edema</li><li>\u2022 econdary</li><li>\u2022 Retinal Vein Occlusion</li><li>\u2022 Diabetic Maculopathy</li><li>\u2022 0.7mg of Dexamethasone is incorporated into this Implant .</li><li>\u2022 0.7mg</li><li>\u2022 Dexamethasone</li><li>\u2022 incorporated</li><li>\u2022 Implant</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Intravitreal Dexamethasone Implant contains 700 mcg of Dexamethasaone .</li><li>\u27a4 Intravitreal Dexamethasone Implant</li><li>\u27a4 700 mcg</li><li>\u27a4 Dexamethasaone</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 521</li><li>\u27a4 Ref:</li><li>\u27a4 KANSKI 9 TH EDITION PAGE 521</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "22c1696b",
      "audio": ""
    },
    {
      "text": "Ocriplasmin is used in treatment of:",
      "options": [
        {
          "label": "A",
          "text": "Diabetic Macular Edema",
          "correct": false
        },
        {
          "label": "B",
          "text": "Keratoconus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitreomacular Traction",
          "correct": true
        },
        {
          "label": "D",
          "text": "Primary Open Angle Glaucoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Vitreomacular Traction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Vitreomacular Traction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Diabetic Macular Edema (DME) is a complication of Diabetes characterized by Intraretinal Fluid Accumulation due to Microleakage from capillaries . Treatments for DME typically involve Anti-VEGF Injections, Corticosteroids , and Laser Therapy .</li><li>\u2022 Option A</li><li>\u2022 Diabetes</li><li>\u2022 Intraretinal Fluid Accumulation</li><li>\u2022 Microleakage</li><li>\u2022 capillaries</li><li>\u2022 Anti-VEGF Injections, Corticosteroids</li><li>\u2022 Laser Therapy</li><li>\u2022 Option B . Keratoconus is a Degenerative Disorder of the Cornea characterised by thinning and Ectasia which cause the Cornea to become Conical in shape . Treatment options for keratoconus include corneal cross-linking , custom soft contact lenses , and corneal transplant in advanced cases.</li><li>\u2022 Option B</li><li>\u2022 Degenerative Disorder</li><li>\u2022 Cornea</li><li>\u2022 thinning</li><li>\u2022 Ectasia</li><li>\u2022 Cornea</li><li>\u2022 become Conical</li><li>\u2022 shape</li><li>\u2022 keratoconus</li><li>\u2022 corneal cross-linking</li><li>\u2022 custom soft contact lenses</li><li>\u2022 corneal transplant</li><li>\u2022 Option D . The primary treatments for Primary Open Angle Glaucoma (POAG) are medications that reduce intraocular pressure , laser therapy , and surgical procedures .</li><li>\u2022 Option D</li><li>\u2022 Primary Open Angle Glaucoma (POAG)</li><li>\u2022 medications</li><li>\u2022 reduce intraocular pressure</li><li>\u2022 laser therapy</li><li>\u2022 surgical procedures</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ocriplasmin is primarily used in the treatment of Vitreomacular Traction (VMT) . It works by enzymatically dissolving the proteins that cause the vitreous to adhere to the macula , thus relieving the traction that can impair vision .</li><li>\u27a4 treatment</li><li>\u27a4 Vitreomacular Traction (VMT)</li><li>\u27a4 enzymatically dissolving</li><li>\u27a4 proteins</li><li>\u27a4 cause</li><li>\u27a4 vitreous</li><li>\u27a4 adhere</li><li>\u27a4 macula</li><li>\u27a4 relieving</li><li>\u27a4 traction</li><li>\u27a4 can impair vision</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 597</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 597</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d257359",
      "audio": ""
    },
    {
      "text": "The secondary vitreous concentrates the primary vitreous towards the center of the eye, creating the Canal of Cloquet, which contains a substance that is less optically dense than the secondary vitreous. Where is this secondary vitreous derived from?",
      "options": [
        {
          "label": "A",
          "text": "Surface Ectoderm",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neuroectoderm",
          "correct": true
        },
        {
          "label": "C",
          "text": "Mesoderm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paraxial Mesenchyme",
          "correct": false
        }
      ],
      "correct_answer": "B. Neuroectoderm",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/screenshot-2024-01-29-140720.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Neuroectoderm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . The surface ectoderm: contributes to several structures in the eye , such as the lens and cornea , but it is not the source of the secondary vitreous. The surface ectoderm mainly gives rise to structures at the very front of the eye .</li><li>\u2022 Option A</li><li>\u2022 The surface ectoderm:</li><li>\u2022 several structures</li><li>\u2022 eye</li><li>\u2022 lens</li><li>\u2022 cornea</li><li>\u2022 gives rise</li><li>\u2022 structures</li><li>\u2022 very front</li><li>\u2022 eye</li><li>\u2022 Option C . The mesoderm: contributes to various structures in the eye , including the sclera and the uveal tract ( iris , ciliary body , and choroid ), but it is not the source of the secondary vitreous.</li><li>\u2022 Option C</li><li>\u2022 The mesoderm:</li><li>\u2022 eye</li><li>\u2022 sclera</li><li>\u2022 uveal tract</li><li>\u2022 iris</li><li>\u2022 ciliary body</li><li>\u2022 choroid</li><li>\u2022 Option D . Paraxial mesenchyme contributes to structures in the orbit and extraocular muscles , but it does not give rise to the secondary vitreous in the eye.</li><li>\u2022 Option D</li><li>\u2022 Paraxial mesenchyme</li><li>\u2022 structures</li><li>\u2022 orbit</li><li>\u2022 extraocular muscles</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The secondary vitreous of the eye is derived from the neuroectoderm .</li><li>\u27a4 secondary vitreous</li><li>\u27a4 eye</li><li>\u27a4 neuroectoderm</li><li>\u27a4 Ref: Pg 12/ COMPREHENSIVE Ophthalmology/ 6 th Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 12/ COMPREHENSIVE Ophthalmology/ 6 th Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "381b41b3",
      "audio": ""
    },
    {
      "text": "A 55-year-old male patient, who is a known case of type 2 diabetes and recurrent myocardial infarction, presents to the ophthalmology clinic complaining of blurred vision in his left eye. He reports that his vision has gradually deteriorated over the past few months. Fundus examination reveals signs of diabetic retinopathy. OCT imaging confirms the presence of macular edema in the left eye. Based on the clinical scenario and findings, the patient is diagnosed with diabetic macular edema. Which is the intravitreal agent preferred in this case?",
      "options": [
        {
          "label": "A",
          "text": "Pegaptanib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aflibercept",
          "correct": false
        },
        {
          "label": "C",
          "text": "Triamcinolone Acetonide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Bevacizumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Triamcinolone Acetonide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Triamcinolone Acetonide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . An anti-VEGF ( Vascular Endothelial Growth Factor ) agent , Pegaptanib was one of the first agents of this class to be used for ocular conditions . However, it is not the most commonly used or preferred agent for DME due to its selective VEGF isoform binding .</li><li>\u2022 Option A</li><li>\u2022 anti-VEGF</li><li>\u2022 Vascular Endothelial Growth Factor</li><li>\u2022 agent</li><li>\u2022 Pegaptanib</li><li>\u2022 first agents</li><li>\u2022 ocular conditions</li><li>\u2022 preferred agent</li><li>\u2022 DME</li><li>\u2022 selective VEGF isoform binding</li><li>\u2022 Option B . Aflibercept is a widely used and highly effective anti-VEGF agent for the treatment of DME . Aflibercept has been shown to be effective in reducing macular edema and improving visual acuity in patients with DME . It binds all forms of VEGF-A , as well as placental growth factor , which are key in the pathogenesis of DME .</li><li>\u2022 Option B</li><li>\u2022 widely used</li><li>\u2022 highly effective anti-VEGF agent</li><li>\u2022 DME</li><li>\u2022 effective</li><li>\u2022 reducing macular edema</li><li>\u2022 improving visual acuity</li><li>\u2022 DME</li><li>\u2022 VEGF-A</li><li>\u2022 placental growth factor</li><li>\u2022 pathogenesis</li><li>\u2022 DME</li><li>\u2022 Option D Bevacizumab is another anti-VEGF agent used off-label for DME . It is effective in reducing macular edema and improving vision but is not FDA-approved for this indication. However, it is often used due to its cost-effectiveness .</li><li>\u2022 Option D</li><li>\u2022 another anti-VEGF agent</li><li>\u2022 off-label</li><li>\u2022 DME</li><li>\u2022 effective</li><li>\u2022 reducing macular edema</li><li>\u2022 improving vision</li><li>\u2022 due</li><li>\u2022 cost-effectiveness</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 In a patient with diabetic macular edema and a significant cardiac history , intravitreal steroid injection ( Triamcinolone acetonide / Dexamethasone implant ) is a preferred choice due to its effectiveness in treating DME and a favourable safety profile .</li><li>\u27a4 diabetic macular edema</li><li>\u27a4 significant cardiac history</li><li>\u27a4 intravitreal steroid injection</li><li>\u27a4 Triamcinolone acetonide</li><li>\u27a4 Dexamethasone implant</li><li>\u27a4 effectiveness</li><li>\u27a4 treating DME</li><li>\u27a4 favourable safety profile</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 508</li><li>\u27a4 Ref:</li><li>\u27a4 KANSKI 9 TH EDITION PAGE 508</li><li>\u27a4 2. Giridhar S, Verma L, Rajendran A, Bhende M, Goyal M, Ramasamy K, Rajalakshmi, Padmaja R, Natarajan S, Palanivelu MS, Raman R, Sivaprasad S. Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian J Ophthalmol. 2021 Nov;69(11):3076-3086. doi: 10.4103/ijo.IJO_1469_21. PMID: 34708746; PMCID: PMC8725123.</li><li>\u27a4 2. Giridhar S, Verma L, Rajendran A, Bhende M, Goyal M, Ramasamy K, Rajalakshmi, Padmaja R, Natarajan S, Palanivelu MS, Raman R, Sivaprasad S. Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement. Indian J Ophthalmol. 2021 Nov;69(11):3076-3086. doi: 10.4103/ijo.IJO_1469_21. PMID: 34708746; PMCID: PMC8725123.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b540932e",
      "audio": ""
    },
    {
      "text": "Recommended daily supplementation based on AREDS2 includes all except:",
      "options": [
        {
          "label": "A",
          "text": "Zinc",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin E",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta-Carotene",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lutein",
          "correct": false
        }
      ],
      "correct_answer": "C. Beta-Carotene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Beta-Carotene</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Zinc is included in the AREDS2 formula . It plays a role in maintaining the health of the retina and may help slow the progression of AMD .</li><li>\u2022 Option A</li><li>\u2022 AREDS2 formula</li><li>\u2022 role</li><li>\u2022 maintaining</li><li>\u2022 health</li><li>\u2022 retina</li><li>\u2022 slow</li><li>\u2022 progression</li><li>\u2022 AMD</li><li>\u2022 Option B . Vitamin E is also part of the AREDS2 formula . It is an antioxidant that helps protect cells in the body , including those in the eye , from damage .</li><li>\u2022 Option B</li><li>\u2022 AREDS2 formula</li><li>\u2022 antioxidant</li><li>\u2022 protect cells</li><li>\u2022 body</li><li>\u2022 eye</li><li>\u2022 from damage</li><li>\u2022 Option D . Lutein, along with zeaxanthin , replaced beta-carotene in the AREDS2 formula . These carotenoids are believed to be beneficial for eye health , particularly in reducing the risk or slowing the progression of AMD .</li><li>\u2022 Option D</li><li>\u2022 zeaxanthin</li><li>\u2022 replaced beta-carotene</li><li>\u2022 AREDS2 formula</li><li>\u2022 carotenoids</li><li>\u2022 beneficial</li><li>\u2022 eye health</li><li>\u2022 reducing</li><li>\u2022 risk</li><li>\u2022 slowing</li><li>\u2022 progression</li><li>\u2022 AMD</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Based on the findings of AREDS2 , the recommended daily supplementation for age-related macular degeneration includes zinc , vitamin E , and lutein , but not beta-carotene, which was removed due to its associated risks , particularly in smokers .</li><li>\u27a4 AREDS2</li><li>\u27a4 recommended daily supplementation</li><li>\u27a4 age-related macular degeneration</li><li>\u27a4 zinc</li><li>\u27a4 vitamin E</li><li>\u27a4 lutein</li><li>\u27a4 removed</li><li>\u27a4 associated risks</li><li>\u27a4 smokers</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 576</li><li>\u27a4 Ref:</li><li>\u27a4 KANSKI 9 TH EDITION PAGE 576</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aff0b092",
      "audio": ""
    },
    {
      "text": "Fenretinide is a new agent under trial for which of the following conditions?",
      "options": [
        {
          "label": "A",
          "text": "Retinitis Pigmentosa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diabetic Retinopathy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Central Retinal Vein Occlusion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Age related Macular Degeneration",
          "correct": true
        }
      ],
      "correct_answer": "D. Age related Macular Degeneration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Age related Macular Degeneration</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fenretinide is a new drug under clinical trial in ARMD . Visual cycle modulation occurs by ameliorating the formation of cytotoxic products by reducing the rate of vitamin A processing .</li><li>\u27a4 Fenretinide is a new drug under clinical trial in ARMD .</li><li>\u27a4 Fenretinide</li><li>\u27a4 new drug</li><li>\u27a4 clinical trial</li><li>\u27a4 ARMD</li><li>\u27a4 Visual cycle modulation occurs by ameliorating the formation of cytotoxic products by reducing the rate of vitamin A processing .</li><li>\u27a4 Visual cycle modulation</li><li>\u27a4 ameliorating</li><li>\u27a4 formation</li><li>\u27a4 cytotoxic products</li><li>\u27a4 reducing</li><li>\u27a4 rate</li><li>\u27a4 vitamin A processing</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 576</li><li>\u27a4 Ref:</li><li>\u27a4 KANSKI 9 TH EDITION PAGE 576</li><li>\u27a4 2. Taskintuna I, Elsayed ME, Schatz P. Update on Clinical Trials in Dry Age-related Macular Degeneration. Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):13-26. doi: 10.4103/0974-9233.173134. PMID: 26957835; PMCID: PMC4759891.</li><li>\u27a4 2. Taskintuna I, Elsayed ME, Schatz P. Update on Clinical Trials in Dry Age-related Macular Degeneration. Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):13-26. doi: 10.4103/0974-9233.173134. PMID: 26957835; PMCID: PMC4759891.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "40815ef9",
      "audio": ""
    },
    {
      "text": "Which of the following Anti \u2013 VEGF binds with placental growth factor?",
      "options": [
        {
          "label": "A",
          "text": "Pegaptanib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aflibercept",
          "correct": true
        },
        {
          "label": "C",
          "text": "Ranibizumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bevacizumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Aflibercept",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Aflibercept</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Pegaptanib is an anti-VEGF medication that selectively binds to VEGF-165 isoform . However, it does not bind to placental growth factor.</li><li>\u2022 Option A</li><li>\u2022 Pegaptanib</li><li>\u2022 anti-VEGF medication</li><li>\u2022 selectively binds</li><li>\u2022 VEGF-165</li><li>\u2022 isoform</li><li>\u2022 Option C . Ranibizumab ( Lucentis ) is a monoclonal antibody fragment that binds to and inhibits VEGF-A . It does not bind to placental growth factor.</li><li>\u2022 Option C</li><li>\u2022 Ranibizumab</li><li>\u2022 Lucentis</li><li>\u2022 monoclonal antibody fragment</li><li>\u2022 binds</li><li>\u2022 inhibits VEGF-A</li><li>\u2022 Option D . Bevacizumab ( Avastin ) is a full-length monoclonal antibody that binds to VEGF-A but, like Ranibizumab and Pegaptanib, does not bind to placental growth factor.</li><li>\u2022 Option D</li><li>\u2022 Bevacizumab</li><li>\u2022 Avastin</li><li>\u2022 full-length monoclonal antibody</li><li>\u2022 binds</li><li>\u2022 VEGF-A</li><li>\u2022 Ranibizumab</li><li>\u2022 Pegaptanib,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Aflibercept is unique among the listed anti-VEGF agents in that it binds both to VEGF-A and placental growth factor . This dual binding ability is relevant in its use for treating conditions like wet age-related macular degeneration and diabetic macular edema , where both VEGF and placental growth factor play a role in pathogenesis .</li><li>\u27a4 Aflibercept</li><li>\u27a4 unique</li><li>\u27a4 listed anti-VEGF agents</li><li>\u27a4 binds both</li><li>\u27a4 VEGF-A</li><li>\u27a4 placental growth factor</li><li>\u27a4 dual binding ability</li><li>\u27a4 relevant</li><li>\u27a4 wet age-related macular degeneration</li><li>\u27a4 diabetic macular edema</li><li>\u27a4 both VEGF</li><li>\u27a4 placental growth factor</li><li>\u27a4 pathogenesis</li><li>\u27a4 Ref: KANSKI 9 TH EDITION PAGE 587</li><li>\u27a4 Ref:</li><li>\u27a4 KANSKI 9 TH EDITION PAGE 587</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd88e3e2",
      "audio": ""
    },
    {
      "text": "A 45-year-old male patient with a history of pulmonary tuberculosis presents to the ophthalmology clinic for a routine eye examination. The patient has been on ATT since 4 months. Which type of colour defect is associated with ethambutol, an ATT drug?",
      "options": [
        {
          "label": "A",
          "text": "Red Desaturation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Blue-Green Defect",
          "correct": false
        },
        {
          "label": "C",
          "text": "Green Desaturation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Red-Green Defect",
          "correct": true
        }
      ],
      "correct_answer": "D. Red-Green Defect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Red-Green Defect</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Red Desaturation is not typically associated with ethambutol. Red desaturation is more commonly associated with optic nerve disorders like optic neuritis .</li><li>\u2022 Option A</li><li>\u2022 not typically associated</li><li>\u2022 optic nerve disorders</li><li>\u2022 optic neuritis</li><li>\u2022 Option B . Blue-Green Defect: Ethambutol toxicity can lead to a blue-yellow color vision defect . Blue-yellow defect is the earliest colour defect to develop in ethambutol toxicity , however red-green defect is the commonest .</li><li>\u2022 Option B</li><li>\u2022 Ethambutol toxicity</li><li>\u2022 lead</li><li>\u2022 blue-yellow color vision defect</li><li>\u2022 Blue-yellow defect</li><li>\u2022 earliest colour defect</li><li>\u2022 develop</li><li>\u2022 ethambutol toxicity</li><li>\u2022 red-green defect</li><li>\u2022 commonest</li><li>\u2022 Option C . Green Desaturation: This type of color defect is not typically associated with ethambutol toxicity.</li><li>\u2022 Option C</li><li>\u2022 not typically</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Ethambutol , an antitubercular therapy drug , is commonly associated with a red-green color vision defect .</li><li>\u27a4 Ethambutol</li><li>\u27a4 antitubercular therapy</li><li>\u27a4 drug</li><li>\u27a4 red-green color</li><li>\u27a4 vision defect</li><li>\u27a4 Ref: PARSONS DISEASES OF EYE 22 ND EDITION PAGE 244</li><li>\u27a4 Ref:</li><li>\u27a4 PARSONS DISEASES OF EYE 22 ND EDITION PAGE 244</li><li>\u27a4 2. Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, Prakash A, Lodha R, Mohan A, Menon V, Garg R. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. Indian J Ophthalmol. 2021 Dec;69(12):3734-3739. doi: 10.4103/ijo.IJO_3746_20. PMID: 34827033; PMCID: PMC8837289</li><li>\u27a4 2. Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, Prakash A, Lodha R, Mohan A, Menon V, Garg R. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. Indian J Ophthalmol. 2021 Dec;69(12):3734-3739. doi: 10.4103/ijo.IJO_3746_20. PMID: 34827033; PMCID: PMC8837289</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3c20e69",
      "audio": ""
    },
    {
      "text": "Maximum allowed dosage of hydroxychloroquine to avoid development of Bull\u2019s eye maculopathy is?",
      "options": [
        {
          "label": "A",
          "text": "4.5mg/kg/day",
          "correct": true
        },
        {
          "label": "B",
          "text": "5.5mg/kg/day",
          "correct": false
        },
        {
          "label": "C",
          "text": "6.5mg/kg/day",
          "correct": false
        },
        {
          "label": "D",
          "text": "7/5mg/kg/day",
          "correct": false
        }
      ],
      "correct_answer": "A. 4.5mg/kg/day",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 4.5mg/kg/day</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 As per the American Academy of Ophthalmology Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy - 2016 , the limit for maximum daily HCQ use is < 5.0 mg/kg real weight , which correlates better with risk than ideal weight . There are no similar demographic data for CQ, but dose comparisons in older literature suggest using <2.3 mg/kg real weight. Screening for toxicity: A baseline fundus examination should be performed to rule out preexisting maculopathy . Annual screening after 5 years for patients on acceptable doses and without major risk factors . Screening Tests: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients . The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields , and fundus autofluorescence (FAF) can show damage topographically. Modern screening should detect retinopathy before it is visible in the fundus</li><li>\u2022 As per the American Academy of Ophthalmology Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy - 2016 , the limit for maximum daily HCQ use is < 5.0 mg/kg real weight , which correlates better with risk than ideal weight . There are no similar demographic data for CQ, but dose comparisons in older literature suggest using <2.3 mg/kg real weight.</li><li>\u2022 American Academy of Ophthalmology</li><li>\u2022 Chloroquine</li><li>\u2022 Hydroxychloroquine Retinopathy</li><li>\u2022 maximum daily HCQ</li><li>\u2022 < 5.0 mg/kg real weight</li><li>\u2022 correlates</li><li>\u2022 risk</li><li>\u2022 than</li><li>\u2022 ideal weight</li><li>\u2022 Screening for toxicity: A baseline fundus examination should be performed to rule out preexisting maculopathy .</li><li>\u2022 baseline fundus examination</li><li>\u2022 performed</li><li>\u2022 rule out preexisting maculopathy</li><li>\u2022 Annual screening after 5 years for patients on acceptable doses and without major risk factors .</li><li>\u2022 Annual screening</li><li>\u2022 after 5 years</li><li>\u2022 acceptable</li><li>\u2022 doses</li><li>\u2022 without major risk factors</li><li>\u2022 Screening Tests: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients .</li><li>\u2022 automated visual fields</li><li>\u2022 spectral-domain optical coherence tomography (SD OCT).</li><li>\u2022 beyond</li><li>\u2022 central macula</li><li>\u2022 Asian patients</li><li>\u2022 The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields , and fundus autofluorescence (FAF) can show damage topographically.</li><li>\u2022 multifocal electroretinogram (mfERG)</li><li>\u2022 objective corroboration</li><li>\u2022 visual fields</li><li>\u2022 fundus autofluorescence (FAF)</li><li>\u2022 damage topographically.</li><li>\u2022 Modern screening should detect retinopathy before it is visible in the fundus</li><li>\u2022 Modern screening</li><li>\u2022 detect retinopathy</li><li>\u2022 before</li><li>\u2022 visible</li><li>\u2022 fundus</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Maximum allowed dosage of hydroxychloroquine to avoid development of Bull\u2019s eye maculopathy is 4.5mg/kg/day .</li><li>\u27a4 avoid</li><li>\u27a4 Bull\u2019s eye maculopathy</li><li>\u27a4 4.5mg/kg/day</li><li>\u27a4 Ref: PARSONS DISEASES OF EYE 22 ND EDITION PAGE 367</li><li>\u27a4 Ref:</li><li>\u27a4 PARSONS DISEASES OF EYE 22 ND EDITION PAGE 367</li><li>\u27a4 2. https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h</li><li>\u27a4 2.</li><li>\u27a4 https://www.aao.org/education/clinical-statement/revised-recommendations-on-screening-chloroquine-h</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b9ef1708",
      "audio": ""
    },
    {
      "text": "The location of the fovea is described as being 2 DD away from the optic disc. What is the normal Disc Diameter (DD)?",
      "options": [
        {
          "label": "A",
          "text": "1.5 mm",
          "correct": true
        },
        {
          "label": "B",
          "text": "2 mm",
          "correct": false
        },
        {
          "label": "C",
          "text": "2.5 mm",
          "correct": false
        },
        {
          "label": "D",
          "text": "3 mm",
          "correct": false
        }
      ],
      "correct_answer": "A. 1.5 mm",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture3_eCOmSlZ.jpg"
      ],
      "explanation": "<p><strong>Ans. A) 1.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The diameter of the optic disc is 1.5mm .</li><li>\u2022 diameter</li><li>\u2022 optic disc</li><li>\u2022 1.5mm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The size of the optic disc is 1.5mm</li><li>\u27a4 size</li><li>\u27a4 1.5mm</li><li>\u27a4 Ref: Pg 166/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 166/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "86a548de",
      "audio": ""
    },
    {
      "text": "How much is the diameter of the Macula Lutea?",
      "options": [
        {
          "label": "A",
          "text": "2.5 mm",
          "correct": false
        },
        {
          "label": "B",
          "text": "3.5 mm",
          "correct": false
        },
        {
          "label": "C",
          "text": "4.5 mm",
          "correct": false
        },
        {
          "label": "D",
          "text": "5.5 mm",
          "correct": true
        }
      ],
      "correct_answer": "D. 5.5 mm",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture4_aUcZQQS.jpg"
      ],
      "explanation": "<p><strong>Ans. D) 5.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Diameter of Macula Lutea is 5.5 mm .</li><li>\u2022 Diameter</li><li>\u2022 Macula Lutea</li><li>\u2022 5.5 mm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The size of the macula lutea is 5.5 mm.</li><li>\u27a4 size</li><li>\u27a4 macula lutea</li><li>\u27a4 5.5 mm.</li><li>\u27a4 Ref: Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cbff2763",
      "audio": ""
    },
    {
      "text": "The Fovea centralis is responsible for the visual acuity of a person. How much is its diameter?",
      "options": [
        {
          "label": "A",
          "text": "1 mm",
          "correct": false
        },
        {
          "label": "B",
          "text": "1.5 mm",
          "correct": true
        },
        {
          "label": "C",
          "text": "2.5 mm",
          "correct": false
        },
        {
          "label": "D",
          "text": "3.5 mm",
          "correct": false
        }
      ],
      "correct_answer": "B. 1.5 mm",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture5_PD4Fgy1.jpg"
      ],
      "explanation": "<p><strong>Ans. B) 1.5 mm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The diameter of fovea is 1.5 mm .</li><li>\u2022 diameter</li><li>\u2022 fovea</li><li>\u2022 1.5 mm</li><li>\u2022 Ref: Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u2022 Ref:</li><li>\u2022 Pg 167 / Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e95e6996",
      "audio": ""
    },
    {
      "text": "The insertion of which of these muscles is closest to the macula?",
      "options": [
        {
          "label": "A",
          "text": "Inferior Oblique",
          "correct": true
        },
        {
          "label": "B",
          "text": "Inferior Rectus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Levator Palpebrae Superioris",
          "correct": false
        },
        {
          "label": "D",
          "text": "Superior Rectus",
          "correct": false
        }
      ],
      "correct_answer": "A. Inferior Oblique",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture6_JofgII5.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Inferior Oblique</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . The inferior rectus muscle inserts on the anterior , inferior surface of the eye . It moves the eye downward .</li><li>\u2022 Option B</li><li>\u2022 anterior</li><li>\u2022 inferior surface</li><li>\u2022 eye</li><li>\u2022 eye downward</li><li>\u2022 Option C . Levator Palpebrae Superioris is responsible for elevating the upper eyelid and does not directly influence eye movement or attachment to the eyeball in a way that would bring it close to the macula.</li><li>\u2022 Option C</li><li>\u2022 elevating</li><li>\u2022 upper eyelid</li><li>\u2022 Option D . Inserting on the anterior , superior surface of the eyeball , the superior rectus elevates the eye .</li><li>\u2022 Option D</li><li>\u2022 anterior</li><li>\u2022 superior surface</li><li>\u2022 eyeball</li><li>\u2022 elevates</li><li>\u2022 eye</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 When considering the anatomical relationship between the extraocular muscles and the macula , the inferior oblique muscle inserts posterior to the equator of the eye while the rectii insert anterior to the equator of the eye .</li><li>\u27a4 extraocular muscles</li><li>\u27a4 macula</li><li>\u27a4 inferior oblique muscle</li><li>\u27a4 posterior</li><li>\u27a4 equator</li><li>\u27a4 rectii insert</li><li>\u27a4 anterior</li><li>\u27a4 equator</li><li>\u27a4 eye</li><li>\u27a4 Ref: Pg 360/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 360/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 2. https://eyewiki.org/Extraocular_Muscles</li><li>\u27a4 2.</li><li>\u27a4 https://eyewiki.org/Extraocular_Muscles</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9e2c24d6",
      "audio": ""
    },
    {
      "text": "Henle\u2019s Layer is the thickened Outer Plexiform Layer in which of the following region?",
      "options": [
        {
          "label": "A",
          "text": "Parafoveal",
          "correct": false
        },
        {
          "label": "B",
          "text": "Foveal",
          "correct": true
        },
        {
          "label": "C",
          "text": "Optic disc",
          "correct": false
        },
        {
          "label": "D",
          "text": "Periphery",
          "correct": false
        }
      ],
      "correct_answer": "B. Foveal",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Foveal</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . The parafoveal area is the region surrounding the fovea. While it is a significant part of the macula and has a high density of photoreceptors , Henle's layer is not specifically characterized as being thickened in this region.</li><li>\u2022 Option A</li><li>\u2022 significant part</li><li>\u2022 macula</li><li>\u2022 high density</li><li>\u2022 photoreceptors</li><li>\u2022 Option C . The optic disc, where the optic nerve exits the eye , does not contain photoreceptors, and therefore does not have Henle's layer. This region is known as the blind spot because it lacks photoreceptors.</li><li>\u2022 Option C</li><li>\u2022 optic nerve</li><li>\u2022 exits</li><li>\u2022 eye</li><li>\u2022 blind spot</li><li>\u2022 lacks photoreceptors.</li><li>\u2022 Option D . The peripheral retina is important for peripheral vision and is rich in rods , but it does not feature the thickened Henle's layer that is characteristic of the fovea .</li><li>\u2022 Option D</li><li>\u2022 peripheral retina</li><li>\u2022 peripheral vision</li><li>\u2022 rich</li><li>\u2022 rods</li><li>\u2022 characteristic</li><li>\u2022 fovea</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Henle\u2019s layer is a thickened part of the outer plexiform layer predominantly found in the foveal region of the retina .</li><li>\u27a4 Henle\u2019s layer</li><li>\u27a4 thickened part</li><li>\u27a4 outer plexiform layer</li><li>\u27a4 foveal region</li><li>\u27a4 retina</li><li>\u27a4 Ref: Pg 172/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 172/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0f210442",
      "audio": ""
    },
    {
      "text": "A 30-year-old patient diagnosed with Best Vitelliform Dystrophy, characterized by the classic \"Egg-Yolk\" appearance in the fundus examination, is evaluated for Retinal function. Given this Hereditary Retinal Disorder's typical Fundus findings and its pathophysiology, which of the following statements most accurately describes the expected results of electrophysiological testing in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Electrooculography (EOG) will likely show a normal light peak, while Electroretinography (ERG) will demonstrate Abnormal Rod and Cone responses.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Both EOG and ERG will show significantly diminished responses due to Generalized Retinal Dysfunction.",
          "correct": false
        },
        {
          "label": "C",
          "text": "EOG will likely show an Abnormal Arden Ratio, while ERG will remain Normal or Minimally Affected.",
          "correct": true
        },
        {
          "label": "D",
          "text": "ERG will reveal a significant reduction in B-Wave Amplitude, while EOG will show a Normal Dark Trough.",
          "correct": false
        }
      ],
      "correct_answer": "C. EOG will likely show an Abnormal Arden Ratio, while ERG will remain Normal or Minimally Affected.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) EOG will likely show an Abnormal Arden Ratio, while ERG will remain Normal or Minimally Affected.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . This choice is incorrect . In Best vitelliform dystrophy , the primary abnormality is detected in the EOG , not the ERG. The ERG generally remains normal or minimally affected , as the primary pathology is in the retinal pigment epithelium rather than the photoreceptors.</li><li>\u2022 Option A</li><li>\u2022 incorrect</li><li>\u2022 Best vitelliform dystrophy</li><li>\u2022 primary abnormality</li><li>\u2022 detected</li><li>\u2022 EOG</li><li>\u2022 remains normal</li><li>\u2022 minimally affected</li><li>\u2022 primary pathology</li><li>\u2022 retinal pigment epithelium</li><li>\u2022 Option B . This is not typically seen in Best vitelliform dystrophy . While the EOG shows abnormalities , the ERG is usually normal or only slightly affected , as the disorder primarily affects the retinal pigment epithelium .</li><li>\u2022 Option B</li><li>\u2022 not</li><li>\u2022 Best vitelliform dystrophy</li><li>\u2022 EOG shows abnormalities</li><li>\u2022 ERG</li><li>\u2022 usually normal</li><li>\u2022 only slightly affected</li><li>\u2022 disorder primarily affects</li><li>\u2022 retinal pigment epithelium</li><li>\u2022 Option D . This choice is incorrect . In Best vitelliform dystrophy , the significant abnormality is observed in the EOG , not the ERG. The ERG , which measures photoreceptor function , is generally normal or only slightly affected .</li><li>\u2022 Option D</li><li>\u2022 incorrect</li><li>\u2022 Best vitelliform dystrophy</li><li>\u2022 significant abnormality</li><li>\u2022 observed</li><li>\u2022 EOG</li><li>\u2022 ERG</li><li>\u2022 photoreceptor function</li><li>\u2022 generally normal</li><li>\u2022 only slightly affected</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 In Best vitelliform dystrophy , electrooculography (EOG) typically shows an abnormal Arden ratio , indicating retinal pigment epithelium dysfunction , while electroretinography (ERG) remains normal or minimally affected .</li><li>\u27a4 Best vitelliform dystrophy</li><li>\u27a4 electrooculography (EOG)</li><li>\u27a4 abnormal Arden ratio</li><li>\u27a4 retinal pigment epithelium</li><li>\u27a4 dysfunction</li><li>\u27a4 electroretinography (ERG)</li><li>\u27a4 normal</li><li>\u27a4 minimally affected</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7604531f",
      "audio": ""
    },
    {
      "text": "A 55-year-old patient presents with visual disturbances and complains of difficulty seeing objects clearly. During the examination, you suspect dysfunction in the visual pathway and decide to assess the first order neuron of the pathway. Which of the following serve as the first order neurons in the visual pathway?",
      "options": [
        {
          "label": "A",
          "text": "Ganglion Cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bipolar Cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Rods & Cones",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "B. Bipolar Cells",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture7_7la8YiB.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Bipolar Cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Ganglion cells are the second order neurons in the visual pathway . They receive signals from the bipolar cells and their axons form the optic nerve , carrying the visual information to the brain .</li><li>\u2022 Option A</li><li>\u2022 Ganglion cells</li><li>\u2022 second order neurons</li><li>\u2022 visual pathway</li><li>\u2022 bipolar cells</li><li>\u2022 axons</li><li>\u2022 optic nerve</li><li>\u2022 carrying</li><li>\u2022 visual information</li><li>\u2022 brain</li><li>\u2022 Option C . Rods & Cones are the photoreceptors located in the retina and are responsible for converting light into electrical signals . These signals are then transmitted to the bipolar cells .</li><li>\u2022 Option C</li><li>\u2022 photoreceptors</li><li>\u2022 retina</li><li>\u2022 responsible</li><li>\u2022 converting light</li><li>\u2022 electrical signals</li><li>\u2022 transmitted</li><li>\u2022 bipolar</li><li>\u2022 cells</li><li>\u2022 Option D. None of the Above.</li><li>\u2022 Option D. None of the Above.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The first order neurons in the visual pathway is the bipolar cells .</li><li>\u27a4 first order neurons</li><li>\u27a4 visual pathway</li><li>\u27a4 bipolar cells</li><li>\u27a4 Ref: Pg 172/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref: Pg 172/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2902340c",
      "audio": ""
    },
    {
      "text": "Which of the following is the 3 rd order Neuron in the Visual Pathway?",
      "options": [
        {
          "label": "A",
          "text": "Axons from Lateral Geniculate Body",
          "correct": true
        },
        {
          "label": "B",
          "text": "Visual Cortex",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ganglion Cells",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bipolar Cells",
          "correct": false
        }
      ],
      "correct_answer": "A. Axons from Lateral Geniculate Body",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture8.jpg"
      ],
      "explanation": "<p><strong>Ans. A)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . The visual cortex, located in the occipital lobe of the brain , is the destination of the visual pathway , where the third-order neurons terminate and the processing of visual information occurs. However, the visual cortex itself is not a neuron, but rather a brain region composed of many neurons.</li><li>\u2022 Option B</li><li>\u2022 occipital lobe</li><li>\u2022 brain</li><li>\u2022 destination</li><li>\u2022 visual pathway</li><li>\u2022 third-order neurons terminate</li><li>\u2022 processing</li><li>\u2022 visual information</li><li>\u2022 Option C . The ganglion cells in the retina are the second-order neurons in the visual pathway . Their axons form the optic nerve , which carries visual information to the brain. They receive input from the bipolar cells ( first-order neurons ) and transmit signals to the LGB .</li><li>\u2022 Option C</li><li>\u2022 second-order neurons</li><li>\u2022 visual pathway</li><li>\u2022 axons</li><li>\u2022 optic nerve</li><li>\u2022 visual information</li><li>\u2022 brain.</li><li>\u2022 receive input</li><li>\u2022 bipolar cells</li><li>\u2022 first-order neurons</li><li>\u2022 transmit</li><li>\u2022 signals</li><li>\u2022 LGB</li><li>\u2022 Option D . Bipolar cells are the first-order neurons in the visual pathway . They receive input from the photoreceptors ( rods and cones ) and transmit signals to the retinal ganglion cells .</li><li>\u2022 Option D</li><li>\u2022 first-order neurons</li><li>\u2022 visual pathway</li><li>\u2022 receive input</li><li>\u2022 photoreceptors</li><li>\u2022 rods</li><li>\u2022 cones</li><li>\u2022 transmit signals</li><li>\u2022 retinal ganglion cells</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The third-order neurons in the visual pathway are the axons from the Lateral Geniculate Body that project to the visual cortex .</li><li>\u27a4 third-order neurons</li><li>\u27a4 visual pathway</li><li>\u27a4 axons</li><li>\u27a4 Lateral Geniculate Body</li><li>\u27a4 project</li><li>\u27a4 visual cortex</li><li>\u27a4 Ref: Pg 184/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 184/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d5075cd",
      "audio": ""
    },
    {
      "text": "Mr. Singh, a 65-year-old with hypertension, undergoes regular eye screening. The ophthalmologist examines his retinal blood vessels and confirms a normal arteriovenous (A: V) ratio. What is the normal A:V ratio of retinal blood vessels?",
      "options": [
        {
          "label": "A",
          "text": "1: 2",
          "correct": false
        },
        {
          "label": "B",
          "text": "1: 3",
          "correct": false
        },
        {
          "label": "C",
          "text": "2: 3",
          "correct": true
        },
        {
          "label": "D",
          "text": "3: 2",
          "correct": false
        }
      ],
      "correct_answer": "C. 2: 3",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/screenshot-2024-01-29-124341.jpg"
      ],
      "explanation": "<p><strong>Ans. C) 2: 3</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The normal artery: vein ratio in the retina is 2:3 .</li><li>\u27a4 normal artery: vein ratio</li><li>\u27a4 retina</li><li>\u27a4 2:3</li><li>\u27a4 Ref: https://www.ncbi.nlm.nih.gov/books/NBK525980/ , Pg 312/ Ch. 20 Diseases of theRetina/ Ed. 22 Parsons Disease of the Eye</li><li>\u27a4 Ref:</li><li>\u27a4 https://www.ncbi.nlm.nih.gov/books/NBK525980/</li><li>\u27a4 , Pg 312/ Ch. 20 Diseases of theRetina/ Ed. 22 Parsons Disease of the Eye</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d48dd52",
      "audio": ""
    },
    {
      "text": "The point of maximum visual acuity on the Retina is?",
      "options": [
        {
          "label": "A",
          "text": "Blind Spot",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fovea Centralis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Macula Lutea",
          "correct": false
        },
        {
          "label": "D",
          "text": "Temporal Retina",
          "correct": false
        }
      ],
      "correct_answer": "B. Fovea Centralis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/screenshot-2024-01-29-125501.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Fovea Centralis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . The blind spot , or optic disc , is the point on the retina where the optic nerve exits the eye . There are no photoreceptors ( rods or cones ) in this area, so it actually corresponds to a lack of visual perception , not maximum acuity.</li><li>\u2022 Option A</li><li>\u2022 blind spot</li><li>\u2022 optic disc</li><li>\u2022 point</li><li>\u2022 retina</li><li>\u2022 optic nerve exits</li><li>\u2022 eye</li><li>\u2022 no photoreceptors</li><li>\u2022 rods</li><li>\u2022 cones</li><li>\u2022 actually corresponds</li><li>\u2022 lack</li><li>\u2022 visual perception</li><li>\u2022 Option C . The macula lutea is an area of the retina that includes the fovea centralis . It is responsible for central vision and contains a high concentration of photoreceptors . However, the specific point of maximum visual acuity is the fovea centralis , not the entire macula lutea.</li><li>\u2022 Option C</li><li>\u2022 area</li><li>\u2022 retina</li><li>\u2022 includes</li><li>\u2022 fovea centralis</li><li>\u2022 responsible</li><li>\u2022 central vision</li><li>\u2022 contains</li><li>\u2022 high concentration</li><li>\u2022 photoreceptors</li><li>\u2022 specific point</li><li>\u2022 maximum visual acuity</li><li>\u2022 fovea centralis</li><li>\u2022 Option D . The temporal retina refers to the portion of the retina situated towards the temporal side of the head . While important for vision, it is not the site of maximum visual acuity. The highest visual acuity is localized in the fovea centralis .</li><li>\u2022 Option D</li><li>\u2022 portion</li><li>\u2022 retina</li><li>\u2022 towards</li><li>\u2022 temporal side</li><li>\u2022 head</li><li>\u2022 highest visual acuity</li><li>\u2022 localized</li><li>\u2022 fovea centralis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The point of maximum visual acuity on the retina is the fovea centralis .</li><li>\u27a4 point</li><li>\u27a4 maximum visual acuity</li><li>\u27a4 retina</li><li>\u27a4 fovea centralis</li><li>\u27a4 Ref: Pg 260/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 260/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4dbdd487",
      "audio": ""
    },
    {
      "text": "Identify the false statement:",
      "options": [
        {
          "label": "A",
          "text": "Deprivation of Glucose for 8 to 10 minutes results in Irreversible Damage.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ability to Discriminate between Different Colours is a Function of Rods.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Retina does not need Insulin for Glucose to Enter the Cells.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Photopic Vision is controlled by Cones.",
          "correct": false
        }
      ],
      "correct_answer": "B. Ability to Discriminate between Different Colours is a Function of Rods.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ability to Discriminate between Different Colours is a Function of Rods.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . This statement is generally true , especially in the context of brain cells . Neurons are highly dependent on a continuous supply of glucose , and deprivation for this length of time can lead to irreversible neuronal damage .</li><li>\u2022 Option A</li><li>\u2022 generally true</li><li>\u2022 context</li><li>\u2022 brain cells</li><li>\u2022 Neurons</li><li>\u2022 highly dependent</li><li>\u2022 continuous supply</li><li>\u2022 glucose</li><li>\u2022 deprivation</li><li>\u2022 length</li><li>\u2022 time</li><li>\u2022 irreversible neuronal damage</li><li>\u2022 Option C. This statement is true . The retina is one of the few tissues in the body that does not require insulin for glucose uptake. Retinal cells can absorb glucose from the bloodstream through insulin-independent mechanisms .</li><li>\u2022 Option C.</li><li>\u2022 true</li><li>\u2022 retina</li><li>\u2022 few tissues</li><li>\u2022 body</li><li>\u2022 Retinal cells</li><li>\u2022 absorb glucose</li><li>\u2022 bloodstream</li><li>\u2022 insulin-independent mechanisms</li><li>\u2022 Option D . This statement is true . Photopic vision refers to vision under well-lit conditions , and it is mediated by cones , which are responsible for high-acuity color vision .</li><li>\u2022 Option D</li><li>\u2022 true</li><li>\u2022 Photopic vision</li><li>\u2022 vision</li><li>\u2022 well-lit conditions</li><li>\u2022 mediated</li><li>\u2022 cones</li><li>\u2022 responsible</li><li>\u2022 high-acuity color vision</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Colour discrimination is a function of cones . Rod cells mediate scotopic vision .</li><li>\u27a4 Colour discrimination</li><li>\u27a4 function</li><li>\u27a4 cones</li><li>\u27a4 Rod cells</li><li>\u27a4 scotopic vision</li><li>\u27a4 Ref: Pg 146/ Anatomy and Physiology of Eye/ AK KHURANA/ 3 rd Edition</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 146/ Anatomy and Physiology of Eye/ AK KHURANA/ 3 rd Edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a727d89",
      "audio": ""
    },
    {
      "text": "ERG (Electroretinogram) is used for the diagnosis & prognosis of which of the following Retinal Disorder(s)?",
      "options": [
        {
          "label": "A",
          "text": "Retinitis Pigmentosa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Retinal Detachment",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diabetic Retinopathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All the above</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Electroretinogram can be used for identifying retinal disorders at an early stage such as:</li><li>\u27a4 Electroretinogram</li><li>\u27a4 identifying retinal disorders</li><li>\u27a4 early stage</li><li>\u27a4 Retinitis Pigmentosa Diabetic Retinopathy Retinal Detachment Vascular Occlusions Chloroquine Toxicity</li><li>\u27a4 Retinitis Pigmentosa</li><li>\u27a4 Diabetic Retinopathy</li><li>\u27a4 Retinal Detachment</li><li>\u27a4 Vascular Occlusions</li><li>\u27a4 Chloroquine Toxicity</li><li>\u27a4 Ref: Pg 235/ Anatomy and Physiology of Eye/ AK KHURANA/ 3 rd Edition</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 235/ Anatomy and Physiology of Eye/ AK KHURANA/ 3 rd Edition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a08f1cd4",
      "audio": ""
    },
    {
      "text": "The important Retinal Vessels are present in which layer of the Retina?",
      "options": [
        {
          "label": "A",
          "text": "Nerve Fibre Layer",
          "correct": true
        },
        {
          "label": "B",
          "text": "Pigment Epithelium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inner Plexiform Layer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Outer Nuclear Layer",
          "correct": false
        }
      ],
      "correct_answer": "A. Nerve Fibre Layer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nerve Fibre Layer</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . The retinal pigment epithelium is a layer of cells located adjacent to the choroid . It plays a critical role in supporting the photoreceptors and maintaining the visual cycle , but it does not contain the retinal blood vessels.</li><li>\u2022 Option B</li><li>\u2022 retinal pigment epithelium</li><li>\u2022 adjacent</li><li>\u2022 choroid</li><li>\u2022 critical role</li><li>\u2022 supporting</li><li>\u2022 photoreceptors</li><li>\u2022 maintaining</li><li>\u2022 visual cycle</li><li>\u2022 Option C . The inner plexiform layer is situated between the inner nuclear layer and the ganglion cell layer . It contains synapses between bipolar cells , amacrine cells , and ganglion cells . Although it is vascularized , it does not contain the main retinal blood vessels.</li><li>\u2022 Option C</li><li>\u2022 inner plexiform layer</li><li>\u2022 inner nuclear layer</li><li>\u2022 ganglion cell layer</li><li>\u2022 synapses</li><li>\u2022 bipolar cells</li><li>\u2022 amacrine cells</li><li>\u2022 ganglion cells</li><li>\u2022 vascularized</li><li>\u2022 Option D . Outer Nuclear Layer contains the cell bodies of the photoreceptors ( rods and cones ) but does not contain the retinal blood vessels.</li><li>\u2022 Option D</li><li>\u2022 Outer Nuclear Layer</li><li>\u2022 cell bodies</li><li>\u2022 photoreceptors</li><li>\u2022 rods</li><li>\u2022 cones</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The important retinal vessels are located in the nerve fiber layer of the retina .</li><li>\u27a4 important retinal vessels</li><li>\u27a4 nerve fiber layer</li><li>\u27a4 retina</li><li>\u27a4 Ref: pg 175/ / anatomy & physiology of eyeball /3 rd edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 pg 175/ / anatomy & physiology of eyeball /3 rd edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "72808766",
      "audio": ""
    },
    {
      "text": "The total number of Short Posterior Ciliary Arteries are?",
      "options": [
        {
          "label": "A",
          "text": "50",
          "correct": false
        },
        {
          "label": "B",
          "text": "20",
          "correct": true
        },
        {
          "label": "C",
          "text": "30",
          "correct": false
        },
        {
          "label": "D",
          "text": "40",
          "correct": false
        }
      ],
      "correct_answer": "B. 20",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture9.jpg"
      ],
      "explanation": "<p><strong>Ans. B) 20</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 There are 10 to 20 short posterior cilliary arteries .</li><li>\u27a4 10</li><li>\u27a4 20 short posterior cilliary arteries</li><li>\u27a4 Ref: Pg 150/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 150/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7c5dbf16",
      "audio": ""
    },
    {
      "text": "Central Retinal Artery is a Branch of?",
      "options": [
        {
          "label": "A",
          "text": "Middle Meningeal Artery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Internal Carotid Artery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ophthalmic Artery",
          "correct": true
        },
        {
          "label": "D",
          "text": "Posterior Cerebral Artery",
          "correct": false
        }
      ],
      "correct_answer": "C. Ophthalmic Artery",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture12.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Ophthalmic Artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Middle Meningeal Artery is a branch of the maxillary artery , which is a terminal branch of the external carotid artery . The middle meningeal artery primarily supplies the meninges of the brain and does not give rise to the central retinal artery.</li><li>\u2022 Option A</li><li>\u2022 Middle Meningeal Artery</li><li>\u2022 branch</li><li>\u2022 maxillary artery</li><li>\u2022 terminal branch</li><li>\u2022 external carotid artery</li><li>\u2022 supplies</li><li>\u2022 meninges</li><li>\u2022 brain</li><li>\u2022 Option B . While the internal carotid artery is a major artery supplying the brain and ophthalmic structures , the central retinal artery specifically is not a direct branch of it. Instead, the internal carotid artery gives rise to the ophthalmic artery , from which the central retinal artery branches off.</li><li>\u2022 Option B</li><li>\u2022 internal carotid artery</li><li>\u2022 major artery</li><li>\u2022 brain</li><li>\u2022 ophthalmic structures</li><li>\u2022 central retinal artery</li><li>\u2022 not a direct branch</li><li>\u2022 gives rise</li><li>\u2022 ophthalmic artery</li><li>\u2022 central retinal artery branches</li><li>\u2022 Option D . The posterior cerebral artery is one of the terminal branches of the basilar artery and supplies parts of the brain , including the occipital lobe and the inferior temporal lobe . It is not involved in the blood supply to the retina or the eye.</li><li>\u2022 Option D</li><li>\u2022 one</li><li>\u2022 terminal branches</li><li>\u2022 basilar artery</li><li>\u2022 supplies</li><li>\u2022 brain</li><li>\u2022 occipital lobe</li><li>\u2022 inferior temporal lobe</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The Central Retinal Artery is a branch of the Ophthalmic Artery</li><li>\u27a4 Central Retinal Artery</li><li>\u27a4 branch</li><li>\u27a4 Ophthalmic Artery</li><li>\u27a4 Ref: Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4cd84844",
      "audio": ""
    },
    {
      "text": "Identify the highlighted structure.",
      "options": [
        {
          "label": "A",
          "text": "Central Retinal Artery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anterior Choroidal Artery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Internal Carotid Artery",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ophthalmic Artery",
          "correct": true
        }
      ],
      "correct_answer": "D. Ophthalmic Artery",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture13.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture14.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Ophthalmic Artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . The Central Retinal Artery originates from the ophthalmic artery , which is a branch of the internal carotid artery .</li><li>\u2022 Option A</li><li>\u2022 originates</li><li>\u2022 ophthalmic artery</li><li>\u2022 branch</li><li>\u2022 internal carotid artery</li><li>\u2022 Option B . The Anterior Choroidal Artery is a branch of the internal carotid artery , typically arising near the origin of the posterior communicating artery .</li><li>\u2022 Option B</li><li>\u2022 branch</li><li>\u2022 internal carotid artery</li><li>\u2022 arising</li><li>\u2022 origin</li><li>\u2022 posterior communicating artery</li><li>\u2022 Option C . The Internal Carotid Artery arises from the common carotid artery in the neck .</li><li>\u2022 Option C</li><li>\u2022 Internal Carotid Artery</li><li>\u2022 common carotid artery</li><li>\u2022 neck</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Ophthalmic Artery is the first major branch of the internal carotid artery once it enters the cranial cavity through the carotid canal .</li><li>\u27a4 first major branch</li><li>\u27a4 internal carotid artery</li><li>\u27a4 enters</li><li>\u27a4 cranial cavity</li><li>\u27a4 carotid canal</li><li>\u27a4 Ref: Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8328a2a6",
      "audio": ""
    },
    {
      "text": "The strongest attachment of the Vitreous Body to the surrounding is at the level of which structure?",
      "options": [
        {
          "label": "A",
          "text": "Vitreous Base",
          "correct": true
        },
        {
          "label": "B",
          "text": "Macula",
          "correct": false
        },
        {
          "label": "C",
          "text": "Optic Disc",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lens",
          "correct": false
        }
      ],
      "correct_answer": "A. Vitreous Base",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture15.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Vitreous Base</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . The vitreous body does not have a strong attachment to the macula. The vitreous is in contact with the macula but does not adhere strongly to it.</li><li>\u2022 Option B</li><li>\u2022 vitreous</li><li>\u2022 contact</li><li>\u2022 macula</li><li>\u2022 Option C . The optic disc is another point of contact for the vitreous body , but it is not the strongest point of attachment. The vitreous can exert traction on the optic disc , particularly in pathological states , but this is not a primary site of firm attachment.</li><li>\u2022 Option C</li><li>\u2022 another point</li><li>\u2022 contact</li><li>\u2022 vitreous body</li><li>\u2022 can exert traction</li><li>\u2022 optic disc</li><li>\u2022 pathological states</li><li>\u2022 Option D . The vitreous body is posterior to the lens and supports its position in the eye . However, the primary attachment of the vitreous body is not at the lens.</li><li>\u2022 Option D</li><li>\u2022 posterior</li><li>\u2022 lens</li><li>\u2022 supports its position</li><li>\u2022 eye</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The strongest attachment of the vitreous body is at the vitreous base , a band of collagen fibers at the ora serrata , crucial for maintaining the structural integrity of the eye.</li><li>\u27a4 strongest attachment</li><li>\u27a4 vitreous body</li><li>\u27a4 vitreous base</li><li>\u27a4 band</li><li>\u27a4 collagen fibers</li><li>\u27a4 ora serrata</li><li>\u27a4 maintaining</li><li>\u27a4 structural integrity</li><li>\u27a4 Ref: Pg 157/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref: Pg 157/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "31d8ce79",
      "audio": ""
    },
    {
      "text": "Short Posterior Ciliary Artery is a Branch of?",
      "options": [
        {
          "label": "A",
          "text": "Long Posterior Ciliary Artery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anterior Ciliary Artery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ophthalmic Artery",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anterior Conjunctival Artery",
          "correct": false
        }
      ],
      "correct_answer": "C. Ophthalmic Artery",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture10.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/picture11.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Ophthalmic Artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . The Long Posterior Ciliary Arteries (there are usually two ) run forward between the sclera and the choroid to supply the ciliary body and the iris . They are distinct and separate from the Short Posterior Ciliary Arteries and do not give rise to them.</li><li>\u2022 Option A</li><li>\u2022 usually two</li><li>\u2022 run forward</li><li>\u2022 sclera</li><li>\u2022 choroid</li><li>\u2022 supply</li><li>\u2022 ciliary body</li><li>\u2022 iris</li><li>\u2022 distinct</li><li>\u2022 separate</li><li>\u2022 Short Posterior Ciliary Arteries</li><li>\u2022 Option B . The Anterior Ciliary Arteries supply the anterior segment of the eye , including the conjunctiva, sclera , and part of the iris . They are not the source of the Short Posterior Ciliary Arteries.</li><li>\u2022 Option B</li><li>\u2022 anterior segment</li><li>\u2022 eye</li><li>\u2022 conjunctiva,</li><li>\u2022 sclera</li><li>\u2022 iris</li><li>\u2022 Option D . Anterior Conjunctival Artery supply the conjunctiva and are not related to the supply of the posterior segment of the eye. They do not give rise to the Short Posterior Ciliary Arteries.</li><li>\u2022 Option D</li><li>\u2022 conjunctiva</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Short Posterior Ciliary Arteries are branches of the Ophthalmic Artery .</li><li>\u27a4 Short Posterior Ciliary Arteries</li><li>\u27a4 branches</li><li>\u27a4 Ophthalmic Artery</li><li>\u27a4 Ref: Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 510/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2874ea4d",
      "audio": ""
    },
    {
      "text": "The Type of Collagen that is not found in Vitreous is?",
      "options": [
        {
          "label": "A",
          "text": "Type 2",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type 4",
          "correct": true
        },
        {
          "label": "C",
          "text": "Type 9",
          "correct": false
        },
        {
          "label": "D",
          "text": "Type 5",
          "correct": false
        }
      ],
      "correct_answer": "B. Type 4",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/29/1542.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Type 4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Type 2 Collagen is indeed found in the vitreous . It is the primary collagen type in the vitreous body , providing structural support and playing a crucial role in maintaining the vitreous gel structure .</li><li>\u2022 Option A</li><li>\u2022 found</li><li>\u2022 vitreous</li><li>\u2022 primary collagen type</li><li>\u2022 vitreous body</li><li>\u2022 structural support</li><li>\u2022 playing</li><li>\u2022 crucial role</li><li>\u2022 maintaining</li><li>\u2022 vitreous gel structure</li><li>\u2022 Option C . Type 9 collagen is also present in the vitreous . It is associated with type 2 collagen and plays a role in the formation of the collagen fibrils that are characteristic of the vitreous body .</li><li>\u2022 Option C</li><li>\u2022 present</li><li>\u2022 vitreous</li><li>\u2022 associated</li><li>\u2022 type 2 collagen</li><li>\u2022 plays</li><li>\u2022 role</li><li>\u2022 formation</li><li>\u2022 collagen fibrils</li><li>\u2022 characteristic</li><li>\u2022 vitreous body</li><li>\u2022 Option D . Type 5 collagen is found in the vitreous . This type of collagen is involved in the formation of the vitreous's fibrillar network, contributing to its structure and function .</li><li>\u2022 Option D</li><li>\u2022 vitreous</li><li>\u2022 collagen</li><li>\u2022 involved</li><li>\u2022 formation</li><li>\u2022 vitreous's fibrillar network,</li><li>\u2022 structure</li><li>\u2022 function</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Type 4 collagen , associated with basement membranes , is not found in the vitreous body of the eye, which primarily contains Type 2 , Type 9 , and Type 5 collagen .</li><li>\u27a4 Type 4 collagen</li><li>\u27a4 basement membranes</li><li>\u27a4 primarily contains</li><li>\u27a4 Type 2</li><li>\u27a4 Type 9</li><li>\u27a4 Type 5 collagen</li><li>\u27a4 Ref: Pg 157/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li><li>\u27a4 Ref:</li><li>\u27a4 Pg 157/ Anatomy & Physiology of Eyeball /3 rd Edition/ AK KHURANA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2e371adc",
      "audio": ""
    },
    {
      "text": "A 68-year-old woman with a history of neovascular age-related macular degeneration (nAMD) presents to the ophthalmology clinic for a follow-up visit. She has been receiving anti-VEGF therapy for the past year with some improvement in her vision. The ophthalmologist discusses the potential use of a newer anti-VEGF agent, brolucizumb. Which of the following is a potential advantage of brolucizumab compared to other anti-VEGF agents in the management of nAMD?",
      "options": [
        {
          "label": "A",
          "text": "Increased Frequency of Administration",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reduced Risk of Intraocular Inflammation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Longer Duration between Injections",
          "correct": true
        },
        {
          "label": "D",
          "text": "Absence of Risk for Geographic Atrophy",
          "correct": false
        }
      ],
      "correct_answer": "C. Longer Duration between Injections",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Longer Duration Between Injections.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . This is incorrect . Brolucizumab , has a longer interval between injections compared to other anti-VEGF agents, which is one of its potential advantages , thereby reducing frequency of injection .</li><li>\u2022 Option A</li><li>\u2022 incorrect</li><li>\u2022 Brolucizumab</li><li>\u2022 longer interval</li><li>\u2022 injections</li><li>\u2022 potential advantages</li><li>\u2022 reducing frequency</li><li>\u2022 injection</li><li>\u2022 Option B . Brolucizumab has been associated with a higher incidence of intraocular inflammation , including rare cases of retinal vasculitis , compared to other anti-VEGF agents.</li><li>\u2022 Option B</li><li>\u2022 Brolucizumab</li><li>\u2022 higher incidence</li><li>\u2022 intraocular inflammation</li><li>\u2022 rare cases</li><li>\u2022 retinal vasculitis</li><li>\u2022 Option D . This is incorrect . All anti-VEGF agents , including brolucizumab , do not eliminate the risk of geographic atrophy in patients with AMD .</li><li>\u2022 Option D</li><li>\u2022 incorrect</li><li>\u2022 All anti-VEGF agents</li><li>\u2022 brolucizumab</li><li>\u2022 geographic atrophy</li><li>\u2022 AMD</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Brolucizumab , a newer anti-VEGF agent for age-related macular degeneration , offers the potential advantage of a longer duration between injections compared to other anti-VEGF agents , which can improve treatment adherence and patient comfort . However, it is associated with a higher risk of intraocular inflammation .</li><li>\u27a4 Brolucizumab</li><li>\u27a4 newer anti-VEGF agent</li><li>\u27a4 age-related macular degeneration</li><li>\u27a4 offers</li><li>\u27a4 potential advantage</li><li>\u27a4 longer duration</li><li>\u27a4 injections</li><li>\u27a4 anti-VEGF agents</li><li>\u27a4 improve treatment</li><li>\u27a4 adherence</li><li>\u27a4 comfort</li><li>\u27a4 higher risk</li><li>\u27a4 intraocular inflammation</li><li>\u27a4 Ref : Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. doi: 10.1159/000513048. Epub 2020 Nov 16. PMID: 33197916.</li><li>\u27a4 Ref</li><li>\u27a4 Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG.</li><li>\u27a4 Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. doi: 10.1159/000513048. Epub 2020 Nov 16. PMID: 33197916.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1601f950",
      "audio": ""
    }
  ]
}